These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 18057668)

  • 1. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
    Suzuki Y
    Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis.
    Verdrengh M; Carlsten H; Ohlsson C; Tarkowski A
    J Orthop Res; 2007 Mar; 25(3):304-10. PubMed ID: 17089391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
    Tanaka Y
    Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate therapy in rheumatoid arthritis.
    Breuil V; Euller-Ziegler L
    Joint Bone Spine; 2006 Jul; 73(4):349-54. PubMed ID: 16616575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
    Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.
    Le Goff B; Soltner E; Charrier C; Maugars Y; Rédini F; Heymann D; Berthelot JM
    Arthritis Res Ther; 2009; 11(6):R185. PubMed ID: 20003278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis.
    Suematsu A; Tajiri Y; Nakashima T; Taka J; Ochi S; Oda H; Nakamura K; Tanaka S; Takayanagi H
    Mod Rheumatol; 2007; 17(1):17-23. PubMed ID: 17278017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Anti-bone resorbing treatment for rheumatoid arthritis.].
    Tanaka Y
    Clin Calcium; 2018; 28(5):630-636. PubMed ID: 29731457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
    Curtis JR; Xie F; Yun H; Saag KG; Chen L; Delzell E
    Arthritis Rheumatol; 2015 Jun; 67(6):1456-64. PubMed ID: 25708920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis.
    Herrak P; Görtz B; Hayer S; Redlich K; Reiter E; Gasser J; Bergmeister H; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2004 Jul; 50(7):2327-37. PubMed ID: 15248234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy of denosumab and bisphosphonates for treating secondary osteoporosis in patients with rheumatoid arthritis.
    Kinoshita H; Miyakoshi N; Kashiwagura T; Kasukawa Y; Sugimura Y; Shimada Y
    Mod Rheumatol; 2017 Jul; 27(4):582-586. PubMed ID: 27659808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological effects of bisphosphonates in patients with rheumatoid arthritis].
    Nagashima M; Shu G; Yamamoto K
    Nihon Rinsho; 2005 Sep; 63(9):1607-12. PubMed ID: 16164219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current topics in drug therapy aiming at bone resorption].
    Yasui T; Tanaka S
    Clin Calcium; 2006 Sep; 16(9):1475-79. PubMed ID: 16951471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.
    Barreira SC; Fonseca JE
    Clin Rev Allergy Immunol; 2016 Aug; 51(1):100-9. PubMed ID: 27166684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis and collagen diseases].
    Sohen S
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():673-6. PubMed ID: 15035207
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
    Miki T; Minamide T
    Clin Calcium; 2007 Jan; 17(1):18-22. PubMed ID: 17211089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid ameliorates the effects of secondary osteoporosis in rheumatoid arthritis patients.
    Xie J; Li S; Xiao L; Ouyang G; Zheng L; Gu Y; Gao C; Han X
    J Orthop Surg Res; 2019 Dec; 14(1):421. PubMed ID: 31823822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases.
    Cantley MD; Bartold PM; Fairlie DP; Rainsford KD; Haynes DR
    J Pharm Pharmacol; 2012 Jun; 64(6):763-74. PubMed ID: 22571254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: environmental protection for the joint?
    Goldring SR; Gravallese EM
    Arthritis Rheum; 2004 Jul; 50(7):2044-7. PubMed ID: 15248201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.